Abcuro

Abcuro is a clinical-stage biotechnology company focused on developing first-in-class immunotherapies for autoimmune diseases and cancer. Their lead program, ulviprubart (ABC008), is designed to selectively deplete cytotoxic T cells, targeting diseases like inclusion body myositis (IBM). The company is currently conducting clinical trials for ulviprubart.

Funding Round: Series C

Funding Amount: $200M

Date: 12-Feb-2025

Investors: NEA, Foresite Capital, RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn Inc., funds and accounts managed by BlackRock, Eurofarma Ventures, Soleus Capital

Markets: Biotech, Health Care, Medical, Therapeutics

HQ: Newton, Massachusetts, United States

Founded: 2015

Website: https://abcuro.com/

LinkedIn: https://www.linkedin.com/company/abcuro-inc/

Twitter: https://twitter.com/AbcuroInc

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/abcuro

Pitchbook: https://pitchbook.com/profiles/company/168930-91